中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Lipoprotein Metabolism and Bacterial Lipopolysaccharide in Parkinson's Disease

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
University of Milan
合作者
Istituti Clinici di Perfezionamento di Milano

关键词

抽象

Patients with Parkinson's disease (PD) present an impaired intestinal permeability with consequent lipopolysaccharide (LPS) translocation in the systemic circulation. Plasmatic lipoproteins play a key role in the detoxification of LPS.
The investigators aim to study the relationships between lipoprotein chemical composition and plasma LPS circulation in PD.

描述

Bacterial lipopolysaccharides are able to produce neuroinflammation and dopaminergic receptors degeneration. In addition, they may produce an accumulation of α-synuclein in the area of the substantia Nigra. Recent studies have shown that α-synuclein aggregates may be present also in gastrointestinal neurons of patients with PD. This last finding led to the hypothesis that the intestine might be an early site of PD disease in response to an environmental toxin or pathogen. Forsyth et al. have discovered an impaired intestinal permeability in subjects with recently diagnosed PD, and they found positive correlations between this factor, exposure to LPS and alpha-synuclein accumulation in gastrointestinal neurons. Plasma lipoproteins play a key role in the detoxification of bacterial endotoxins. Lipoprotein chemical composition is related to their detoxing properties. To the best of investigator knowledge, the relationships between lipoprotein chemical composition and LPS in PD have not yet been investigated. Therefore, the aims of this study are: I) to evaluate the chemical composition of VLDL, LDL and HDL in subjects with PD compared to a control group; 2) to analyze the activity of plasma lipid transfer proteins and LPS plasma levels in the same groups of subjects; III) finally, to investigate the correlations between the analyzed parameters.

Subjects and method Twenty patients with PD and twenty healthy controls were recruited for the study. Fasting blood samples were taken for routine laboratory analysis and for the separation of EDTA plasma. Plasma samples stored at -80°C until were used for lipoprotein isolation and analysis and for the measurement of lipid transfer protein and LPS levels.

日期

最后验证: 04/30/2019
首次提交: 04/15/2019
提交的预估入学人数: 05/01/2019
首次发布: 05/02/2019
上次提交的更新: 05/01/2019
最近更新发布: 05/02/2019
实际学习开始日期: 05/02/2016
预计主要完成日期: 10/19/2017
预计完成日期: 10/19/2017

状况或疾病

Parkinson Disease

干预/治疗

Other: Patients not treated

-

手臂组

干预/治疗
Parkinson's patients
Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
Control group
Subject matched for sex, age and BMI

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Parkinson's patients

Inclusion Criteria:

- Diagnosis of Parkinson disease in agreement with UK Brain Bank

- Farmacological treatment with L-Dopa and/or dopaminergic agonist or diagnosis de novo

- BMI 18.5 - 29.9 kg/m^2

- Informed consent signature

Exclusion criteria:

- Presence of type 1 and type 2 diabetes mellitus

- Presence of major chronic diseases of the digestive tract.

- Pregnancy in progress

- Subjects subjected to antihypertensive therapies or statins or with drugs that can change metabolic status and insulin sensitivity (e.g. chronic oral steroid therapy)

- Subjects affected by endocrine pathologies (e.g. Cushing disease, uncontrolled thyroid disease)

- Presence of known renal insufficiency or creatinine levels greater than 1.8 mg/dl

- Presence of chronic liver disease or ALT and AST levels exceeding two standard deviations from normal levels

- Presence of malignant disease

- Alcohol or drug abuse

- Major psychiatric disorders

- Subjects dedicated to intense and agonistic physical activity.

Control group

Inclusion criteria

- Absence of major disease

- BMI 18.5 - 29.9 kg/m^2

- Informed consent signature

Exclusion Criteria:

- Presence of type 1 and type 2 diabetes mellitus

- Presence of major chronic diseases of the digestive tract.

- Pregnancy in progress

- Subjects subjected to antihypertensive therapies or statins or with drugs that can change metabolic status and insulin sensitivity (e.g. chronic oral steroid therapy)

- Subjects affected by endocrine pathologies (e.g. Cushing disease, uncontrolled thyroid disease)

- Presence of known renal insufficiency or creatinine levels greater than 1.8 mg/dl

- Presence of chronic liver disease or ALT and AST levels exceeding two standard deviations from normal levels

- Presence of malignant disease

- Alcohol or drug abuse

- Major psychiatric disorders

- Subjects dedicated to intense and agonistic physical activity.

结果

主要结果指标

1. LPS [through study completion an average of 1 year]

LPS plasma levels (EU/L)

2. Lipoprotein chemical composition [through study completion an average of 1 year]

Cholesterol (mg/dL); HDL-cholesterol (mg/dL); triglycerides (mg/dL); phospholipids (mg/dL), apoproteins (mg/dL) of VLDL, LDL and HDL

次要成果指标

1. Plasma lipid transfer proteins [through study completion an average of 1 year]

Lipopolysaccharide binding protein (ng/mL), cholesterol ester transfer protein (ng/mL), phospholipid transfer protein (ng/mL)

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge